Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

(2014) C. S. Tam et al.   BLOOD

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia

(2014) J. R. Brown et al.   BLOOD

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

(2014) P. Strati et al.   HAEMATOLOGICA

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

(2014) Jan A Burger et al.   LANCET ONCOLOGY

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center

(2014) D M Stephens et al.   LEUKEMIA

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison†

(2013) I. Herth et al.   ANNALS OF ONCOLOGY

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

(2013) P. Dreger et al.   BLOOD

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia

(2013) Simon E. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

(2013) Susan O'Brien et al.   LANCET ONCOLOGY

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

(2012) M. Ghielmini et al.   ANNALS OF ONCOLOGY

Risk categories and refractory CLL in the era of chemoimmunotherapy

(2012) T. Zenz et al.   BLOOD

Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis

(2012) M A Kharfan-Dabaja et al.   BONE MARROW TRANSPLANTATION

Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: Long-term prospective multicenter study

(2012) Mauricette Michallet et al.   EXPERIMENTAL HEMATOLOGY

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2012) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

(2012) Andrew R. Pettitt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

(2012) Xavier C. Badoux et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome

(2012) J R Brown et al.   LEUKEMIA

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia

(2011) Issa F. Khouri et al.   CANCER

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2011) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

(2010) P. Dreger et al.   BLOOD

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis

(2009) J. Delgado et al.   ANNALS OF ONCOLOGY

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation

(2009) L. Farina et al.   HAEMATOLOGICA

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

(2008) Mohamed L. Sorror et al.   JOURNAL OF CLINICAL ONCOLOGY